| Name | Title | Contact Details |
|---|
Barnabas Health provides treatment and services for more than two million patients each year: 198,000 inpatients and Same Day Surgery patients; 452,000 Emergency Department patients; and 1.5 million outpatients; and delivers more than 18,300 babies annually. Our 18,200 employees, 4,600 physicians and 445 residents and interns are united in our mission to deliver the highest quality of care in the best possible environment. Among our nationally renowned services are: New Jersey’s only certified burn treatment facility, world-class cardiac surgery services for adults; the oldest, most experienced heart transplant program in New Jersey ranked by volume in the top 10 in the nation; the only lung transplant program in New Jersey; one of the country’s most comprehensive robotic surgery services, six nationally certified chest pain centers; accredited certified comprehensive and primary stroke centers, two kidney transplant centers which are in the top 10 of 240 programs in the country; a renowned neurology and neurosurgery program; highly respected assistive reproductive technology program; comprehensive cancer services for adults and children; nationally recognized geriatric services and renowned women’s and children’s services. Throughout Barnabas Health, our dedicated physicians, nurses and health professionals are committed to providing the highest quality of patient care and health education to the community and the region.
PERL Research is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
What if one solution could change everything you thought you knew about Diabetes?
EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company`s pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert`s proven intravitreal drug delivery platform has been safely administered to thousands of patients` eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Orchid Orthopedic Solutions is a Holt, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.